Active pharmaceutical ingredients manufacturer Supriya Lifescience, the 64th listing in 2021, is expected to debut with around 50 percent premium on December 28 Experts cited attractive valuations, strong financial track record with maximum income from exports, increasing growth potential in the pharma space and healthy return ratios for the expectations of the healthy listing.
The initial public offering of Supriya Lifescience received a stellar response from investors, as the issue was subscribed 71.51 times during December 16-20 The allotted quota of non-institutional investors was subscribed 161.22 times, followed by retail investors’ 56.01 times. Qualified institutional buyers also showed strong interest in the public issue, as the portion set aside for them was subscribed 31.83 times.
